Patents by Inventor Rebecca S. Hoffman

Rebecca S. Hoffman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210347875
    Abstract: Multiple-variable dose methods for treating TNFa-related disorders, including Crohn's disease and psoriasis, comprising administering TNFa inhibitors, including TNFa antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: December 17, 2020
    Publication date: November 11, 2021
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan, Susan K. Paulson, Joanna Z. Peng
  • Publication number: 20210347874
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: December 17, 2020
    Publication date: November 11, 2021
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
  • Publication number: 20200017580
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: February 25, 2019
    Publication date: January 16, 2020
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
  • Publication number: 20190062418
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Application
    Filed: March 14, 2018
    Publication date: February 28, 2019
    Inventors: Rebecca S. Hoffman, Mark Weinberg
  • Publication number: 20190055308
    Abstract: Multiple-variable dose methods for treating TNFa-related disorders, including Crohn's disease and psoriasis, comprising administering TNFa inhibitors, including TNFa antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: March 8, 2018
    Publication date: February 21, 2019
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan, Susan K. Paulson, Joanna Z. Peng
  • Publication number: 20180044414
    Abstract: The invention provides methods and compositions for the treatment of a skin disorder associated with detrimental TNF? activity, such as psoriasis. The invention includes methods for treating a skin disorder associated with detrimental TNF? activity, such as psoriasis, in a subject who has failed or lost response to prior biologic therapy, such as prior administration of etanercept. The invention further provides methods for determining the efficacy of a human TNF? antibody, or antigen-binding portion thereof, for the treatment of a skin disorder associated with detrimental TNF? activity, such as psoriasis.
    Type: Application
    Filed: March 27, 2017
    Publication date: February 15, 2018
    Inventors: Martin M. Okun, Rebecca S. Hoffman, Jonathan Barker
  • Publication number: 20170210795
    Abstract: The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of psoriatic arthritis in a subject.
    Type: Application
    Filed: April 13, 2017
    Publication date: July 27, 2017
    Inventors: John R. Medich, Robert L. Wong, Renee J. Perdok, Eric H. Sasso, Rebecca S. Hoffman, Philip Mease, Christopher T. Ritchlin
  • Patent number: 9624295
    Abstract: The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of psoriatic arthritis in a subject.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: April 18, 2017
    Assignee: Abbvie Biotechnology Ltd.
    Inventors: John R. Medich, Robert L. Wong, Renee J. Perdok, Eric H. Sasso, Rebecca S. Hoffman, Phillip Mease, Christopher T. Ritchlin
  • Patent number: 9605064
    Abstract: The invention provides methods and compositions for the treatment of a skin disorder associated with detrimental TNF? activity, such as psoriasis. The invention includes methods for treating a skin disorder associated with detrimental TNF? activity, such as psoriasis, in a subject who has failed or lost response to prior biologic therapy, such as prior administration of etanercept. The invention further provides methods for determining the efficacy of a human TNF? antibody, or antigen-binding portion thereof, for the treatment of a skin disorder associated with detrimental TNF? activity, such as psoriasis.
    Type: Grant
    Filed: August 18, 2010
    Date of Patent: March 28, 2017
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Martin M. Okun, Rebecca S. Hoffman, Jonathan Barker
  • Publication number: 20170044249
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: June 19, 2015
    Publication date: February 16, 2017
    Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan, Susan K Paulson, Joanna Z. Peng
  • Publication number: 20170022271
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: October 7, 2016
    Publication date: January 26, 2017
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
  • Publication number: 20160376360
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Application
    Filed: July 27, 2015
    Publication date: December 29, 2016
    Inventors: Rebecca S. Hoffman, Mark Weinberg, Lori K. Taylor, Elliot K. Chartash, Philip Yan, George R. Granneman
  • Patent number: 9512216
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: December 6, 2016
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Rebecca S. Hoffman, Mark Weinberg, Lori K. Taylor, Elliot K. Chartash, Philip Yan, George R. Granneman
  • Patent number: 9499615
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: November 22, 2016
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
  • Publication number: 20160297879
    Abstract: The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of psoriatic arthritis in a subject.
    Type: Application
    Filed: November 18, 2015
    Publication date: October 13, 2016
    Inventors: Rebecca S. Hoffman, Eric H. Sasso, Renee J. Perdok, Philip Yan, Mark Weinberg, Philip Mease, Christopher T. Ritchlin, Dafna D. Gladman
  • Publication number: 20160272704
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Application
    Filed: June 3, 2016
    Publication date: September 22, 2016
    Inventors: Rebecca S. Hoffman, Mark Weinberg
  • Publication number: 20160200809
    Abstract: The invention provides methods, uses and compositions for the treatment of psoriasis. The invention describes methods and uses for treating psoriasis, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat psoriasis in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of psoriasis in a subject.
    Type: Application
    Filed: August 17, 2015
    Publication date: July 14, 2016
    Inventors: Mary K. Willian, Martin M. Okun, Rebecca S. Hoffman, Yihua Gu, Lisa E. Melilli, Kenneth B. Gordon
  • Publication number: 20160185849
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: July 20, 2015
    Publication date: June 30, 2016
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
  • Publication number: 20160176957
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Application
    Filed: July 27, 2015
    Publication date: June 23, 2016
    Inventors: Rebecca S. Hoffman, Mark Weinberg
  • Publication number: 20150368335
    Abstract: Methods of treating TNF?-related disorders comprising administering TNF? inhibitors, including TNF? antibodies are described.
    Type: Application
    Filed: September 3, 2015
    Publication date: December 24, 2015
    Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, Rebecca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff